- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07470320
Biologie placentaire dans la santé et la maladie
Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.
A major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.
This single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and/or uterine vein blood samples.
Through examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study is a non-interventional, observational study focused on sample collection and laboratory-based analyses to investigate the role of placental EVs and soluble factors in maternal and fetal health. The study will focus on understanding the molecular mechanisms underlying pre-eclampsia, gestational diabetes mellitus and fetal growth restriction, with the ultimate aim of identifying biomarkers and therapeutic targets. To achieve this, the study will recruit participants with healthy, pathological and predisposed pregnancies alongside non-pregnant healthy controls.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Professor Manu Vatish
- Numéro de téléphone: +441865 221009
- E-mail: manu.vatish@wrh.ox.ac.uk
Lieux d'étude
-
-
-
Oxford, Royaume-Uni
- Recrutement
- Oxford University Hospitals NHS Foundation Trust
-
Contact:
- Clinical Research Group
- Numéro de téléphone: +441865 221107
- E-mail: clinicalresearchgroup@wrh.ox.ac.uk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions.
Participants will include:
- Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses.
- Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention.
- Pregnant women with healthy pregnancies to understand normal EV release and immune regulation.
- Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes.
Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.
La description
Inclusion Criteria:
-
Female, aged 18 years or above
-
Willing and able to give informed consent for participation in the study
-
Able to read and understand written and spoken English to comprehend study materials and give informed consent
-
Non-pregnant women in good general health OR pregnant women who fall into one of the following:
- Healthy pregnancy
- Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria
- Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy
- Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities
- Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies
Exclusion Criteria:
- Non-pregnant participants with active health conditions that could confound study outcomes
- Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: OTHER
- Perspectives temporelles: OTHER
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Femmes enceintes diagnostiquées avec une pré-éclampsie
|
There are no interventions for this study |
|
Femmes enceintes diagnostiquées avec un diabète gestationnel
|
There are no interventions for this study |
|
Femmes enceintes diagnostiquées avec un retard de croissance fœtale
|
There are no interventions for this study |
|
Femmes enceintes en bonne santé
|
There are no interventions for this study |
|
Femmes en bonne santé non enceintes
|
There are no interventions for this study |
|
Femmes enceintes prédisposées à la pré-éclampsie
|
There are no interventions for this study |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Enhanced understanding of the molecular and cellular mechanisms linking placental EVs to maternal systemic inflammation in PET and GDM.
Délai: Baseline and at delivery
|
Quantitative (number of particles/ml) and qualitative differences (protein cargo) in EV profiles |
Baseline and at delivery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quantitative and qualitative differences in inflammatory immune cells
Délai: baseline and delivery
|
Quantitative (cells/ml) and qualitative (protein and RNA composition/mg cell) will be measured |
baseline and delivery
|
|
Sensitivity, specificity and predictive value of EVs for identifying PET, GDM and other pregnancy complications
Délai: Baseline and delivery
|
Standard statistical analysis of EV parameters against clinical endpoints to derive sensitivity, specificity and PPV/NPV in these disease conditions |
Baseline and delivery
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies du système endocrinien
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies urogénitales féminines et complications de la grossesse
- Maladies métaboliques
- Complications de grossesse
- Troubles du métabolisme du glucose
- Diabète sucré
- Maladies fœtales
- Troubles de la croissance
- Hypertension
- Maladies et anomalies congénitales, héréditaires et néonatales
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Diabète gestationnel
- Pré-éclampsie
- Retard de croissance fœtale
- Hypertension induite par la grossesse
Autres numéros d'identification d'étude
- 18939
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .